Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.36 |
| ▸ | CA2 | P00918 | 5/20 | 0.36 |
| ▸ | CA9 | Q16790 | 5/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | LPL | P06858 | 2/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | G6PD | P11413 | 1/20 | 0.30 |
| ▸ | IDE | P14735 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30414257 | 0.89 | CA1 (0.35) | CA1CA2CA9CA12CA3 | |
| SCHEMBL26133365 | 0.89 | CA1 (0.35) | CA1CA2CA9CA12CA3 | |
| SCHEMBL29421539 | 0.80 | G6PD (0.37) | CA1CA2CA9CA12CA3 | |
| SCHEMBL395845 | 0.80 | G6PD (0.37) | CA1CA2CA9CA12CA3 | |
| SCHEMBL12205429 | 0.78 | LPL (0.37) | CA1CA2CA9CA12CA3 | |
| SCHEMBL25203833 | 0.77 | CA1 (0.33) | CA1CA2CA9CA12CA3 | |
| SCHEMBL3576002 | 0.77 | CA1 (0.40) | CA1CA2CA9CA12CA3 | |
| SCHEMBL24733131 | 0.76 | LPL (0.42) | CA1CA2CA9CA12CA3 | |
| SCHEMBL2947811 | 0.76 | G6PD (0.37) | CA1CA2CA9CA12CA3 | |
| SCHEMBL22442104 | 0.75 | LPL (0.44) | LPLLIPGP2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348312-A1 | TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | EZH2, DOT1L, EED | CA1 3682/4885CA2 3176/4885CA9 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.